Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Purchases 34,000 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 34,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $49,980.00. Following the purchase, the chairman directly owned 309,000 shares in the company, valued at approximately $454,230. This trade represents a 12.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 21st, Morgan Lee Lekstrom acquired 147,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $1.04 per share, for a total transaction of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Trading Up 1.7%

Shares of NASDAQ STEX traded up $0.03 during midday trading on Thursday, reaching $1.54. 1,870,279 shares of the stock were exchanged, compared to its average volume of 1,907,106. The company has a market capitalization of $279.07 million, a price-to-earnings ratio of -0.16 and a beta of 1.58. Biosig Technologies, Inc. has a twelve month low of $0.70 and a twelve month high of $14.11. The firm has a 50-day moving average price of $1.14.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) EPS for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on STEX shares. Wall Street Zen cut shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, Needham & Company LLC dropped their price target on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.